ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $675,523 | -45.7% | 140,734 | -15.0% | 0.00% | – |
| Q2 2023 | $1,243,288 | +82.8% | 165,551 | +10.0% | 0.00% | – |
| Q1 2023 | $680,133 | -62.3% | 150,472 | -5.9% | 0.00% | -100.0% |
| Q4 2022 | $1,803,031 | +24.3% | 159,985 | +5.6% | 0.00% | 0.0% |
| Q3 2022 | $1,450,000 | +18.1% | 151,502 | -0.1% | 0.00% | – |
| Q2 2022 | $1,228,000 | -45.6% | 151,713 | +13.7% | 0.00% | -100.0% |
| Q1 2022 | $2,256,000 | -25.0% | 133,479 | -4.6% | 0.00% | 0.0% |
| Q4 2021 | $3,007,000 | -70.6% | 139,882 | +0.8% | 0.00% | -66.7% |
| Q3 2021 | $10,245,000 | +102.1% | 138,706 | +49.6% | 0.00% | +50.0% |
| Q2 2021 | $5,070,000 | -24.4% | 92,704 | +1.9% | 0.00% | 0.0% |
| Q1 2021 | $6,709,000 | +8.0% | 90,970 | +26.3% | 0.00% | 0.0% |
| Q4 2020 | $6,210,000 | +184.0% | 72,031 | +24.4% | 0.00% | +100.0% |
| Q3 2020 | $2,187,000 | – | 57,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |